Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0022-5347(17)63068-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Melanoma antigen gene-A2 (MAGE-A2) is one of the most cancer-testis antigens overexpressed in a variety of malignancies. However, the expression of MAGE-A2 for clinical values in the pathophysiology of renal cell carcinoma (RCC) is unknown. For the first time, the present study was conducted to examine the expression and prognostic significance of MAGE-A2 expression in clear cell RCC (ccRCC).
View Article and Find Full Text PDFCorrection: Auskalnis et al. Synchronous Seminoma of Testis and Renal Cell Carcinoma: A Rare Case Report. 2024, , 1553.
Medicina (Kaunas)
December 2024
Department of Genetics and Molecular Medicine, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
In the published publication [...
View Article and Find Full Text PDFEx Vivo Fluorescence Confocal Microscopy Meets Innovation and Revolutionary Technology, for "Real-Time" Histological Evaluation, in Pediatric Surgical Oncology.
Children (Basel)
November 2024
Pediatric Surgery Unit, Salesi Children's Hospital, Polytechnic University of Marche, Via Filippo Corridoni, 16, 60123 Ancona, Italy.
Background And Aim: Ex vivo fluorescence confocal microscopy (FCM) systems are innovative optical imaging tools that create virtual high-resolution histological images without any standard tissue processing, either freezing or fixing in formalin and embedding in paraffin. These systems have opened an era that would revolutionize pathological examination by providing rapid, real-time assessments across various pathology subspecialties, potentially replacing conventional methods that are tissue- and time-consuming. This study aimed to present the first utilization of FCM in pediatric surgical oncology, focusing on assessing the benefits, particularly in facilitating rapid and accurate diagnosis.
View Article and Find Full Text PDFTargeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives.
Explor Target Antitumor Ther
November 2024
Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Advanced urothelial carcinoma (aUC) has a dismal prognosis, with a 5-year survival rate of approximately 10%. Platinum-based chemotherapy has been the backbone of the first-line treatment of aUC for over 40 years. Only in the last decade, the treatment of aUC has evolved and been enriched with new classes of drugs that demonstrated pivotal improvements in terms of oncological responses and, ultimately, survival.
View Article and Find Full Text PDFDEK::AFF2 fusion-associated middle ear non-keratinizing squamous cell carcinoma: A case report.
World J Clin Oncol
December 2024
Department of Pathology, Peking University People's Hospital, Beijing 100044, China.
Background: Primary squamous cell carcinoma (SCC) of the middle ear is rare, with non-keratinizing basaloid types being exceptionally uncommon. Distinguishing these cancers, often caused by viral factors (, human papillomavirus or Epstein-Barr virus), or specific genetic alterations (, bromodomain-containing protein 4-nuclear protein in or gene fused with FLI chromosomal rearrangement), from other cranial conditions, is difficult. The recently identified DEK::AFF2 non-keratinizing SCC (NKSCC) is a novel subtype, fitting the World Health Organization classification of head and neck neoplasms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!